SIGNATUREFD, LLC - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 237 filers reported holding NEKTAR THERAPEUTICS in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.

Quarter-by-quarter ownership
SIGNATUREFD, LLC ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$1,906
+3.5%
3,2000.0%0.00%
Q2 2023$1,841
-18.1%
3,2000.0%0.00%
Q1 2023$2,249
-68.9%
3,2000.0%0.00%
Q4 2022$7,232
-51.8%
3,200
-32.9%
0.00%
-100.0%
Q3 2022$15,000
-25.0%
4,767
-9.1%
0.00%0.0%
Q2 2022$20,000
-23.1%
5,243
+7.8%
0.00%0.0%
Q1 2022$26,000
-52.7%
4,864
+19.5%
0.00%
-50.0%
Q4 2021$55,000
-8.3%
4,070
+21.3%
0.00%0.0%
Q3 2021$60,000
+5.3%
3,355
+1.2%
0.00%0.0%
Q2 2021$57,000
-14.9%
3,314
-1.4%
0.00%
-33.3%
Q1 2021$67,000
+19.6%
3,362
+1.4%
0.00%0.0%
Q4 2020$56,000
+5.7%
3,314
+3.6%
0.00%0.0%
Q3 2020$53,000
-29.3%
3,200
-1.8%
0.00%
-40.0%
Q2 2020$75,000
+29.3%
3,2590.0%0.01%0.0%
Q1 2020$58,000
-17.1%
3,259
+0.9%
0.01%0.0%
Q4 2019$70,000
+12.9%
3,229
-4.8%
0.01%0.0%
Q3 2019$62,000
-46.1%
3,393
+5.3%
0.01%
-50.0%
Q2 2019$115,000
+13.9%
3,221
+7.2%
0.01%
+11.1%
Q1 2019$101,000
+2.0%
3,006
-0.7%
0.01%0.0%
Q4 2018$99,000
-73.2%
3,026
-50.1%
0.01%
-76.3%
Q3 2018$370,000
+12233.3%
6,062
+11125.9%
0.04%
Q2 2018$3,00054
+1700.0%
0.00%
Q1 2018$0
-100.0%
3
-99.7%
0.00%
-100.0%
Q2 2014$13,0001,0000.01%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2021
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders